About the Partner
npj Breast Cancer is published by Springer Nature in partnership with the Breast Cancer Research Foundation (BCRF).
The Breast Cancer Research Foundation (BCRF) is an independent, nonprofit organization dedicated to being the end of breast cancer by advancing the world's most promising research. BCRF funds critical cancer research worldwide with a unique model that spurs innovation to fuel advances in tumor biology, genetics, prevention, treatment, metastasis and survivorship.
BCRF has provided pivotal support to investigators on major national clinical trials that have advanced the clinical management of breast cancer including the TAILORx and MINDACT studies; funded basic research that led to treatment breakthroughs such as the development of PARP inhibitors, CDK 4/6 inhibitors; and was the first breast cancer organization to support immunotherapy research in breast cancer, which has led to the first major trial showing clinical benefit of a checkpoint inhibitor in advanced triple negative breast cancer.
Since its founding in 1993 by Evelyn H. Lauder, BCRF-funded investigators have been involved in every major breakthrough in breast cancer research. In 2018, BCRF awarded $63 million in grants to support the work of nearly 300 scientists at leading medical and academic institutions across 14 countries, making BCRF the largest private funder of breast cancer research worldwide.
Through a unique and streamlined grants program, BCRF seeks out the brightest minds in science and medicine and gives them the necessary resources to pursue their best ideas. As a result, researchers are able to make discoveries and design new approaches to address all aspects of breast cancer—and do so in record time.
BCRF is recognized as one of the most financially efficient nonprofits in the country. They are the highest rated breast cancer organization in the U.S.
The BCRF Mission To prevent and cure breast cancer by advancing the world's most promising research. Visit www.bcrf.org to learn more.